Filing summary
Entity note: The supplied filing is Tivic Health Systems, Inc. (Nasdaq: TIVC), not Valion Bio, Inc. It is a Form 10-Q for the quarter ended June 30, 2023, filed August 14, 2023. Financial figures below are unaudited and generally in millions unless stated otherwise.
Business context and reporting period
Tivic is a commercial-stage bioelectronic medicine company. Its principal commercial product is ClearUP, an FDA-approved handheld device marketed for sinus pain and congestion. The company also conducts research and development into additional applications, including vagus nerve stimulation.
Financial performance and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $0.161 | $0.528 | $0.537 | $0.956 |
| Gross profit | $0.061 | $0.125 | $0.174 | $0.196 |
| Gross margin | 37.9% | 23.7% | 32.4% | 20.5% |
| Operating expenses | $2.186 | $3.143 | $4.415 | $5.454 |
| Net loss | $2.125 | $3.018 | $4.241 | $5.258 |
| Basic and diluted loss per share | $0.07 | $0.32 | $0.17 | $0.55 |
- Cash and cash equivalents were $2.659 million at June 30, 2023, down from $3.517 million at December 31, 2022. Six-month operating cash use was $4.866 million, versus $3.920 million in the prior-year period; investing cash use was $0.118 million.
- Working capital was approximately $2.8 million. Total liabilities were $1.435 million, including $0.460 million in operating lease liabilities. The filing reports no borrowings or other financial debt.
- Total assets were $4.596 million; stockholders’ equity was $3.161 million. Accumulated deficit was $33.883 million.
Changes versus the prior comparable period
- Q2 revenue fell 69.5%; six-month revenue fell 43.8%. Management attributed the declines chiefly to reduced marketing, which coincided with unit sales decreases of 82% in Q2 and 57% in the first half. Higher average selling prices partly offset lower volumes.
- Despite lower revenue, gross margin improved year over year, supported by higher pricing and lower variable manufacturing and fulfillment cost per unit. Low volume increased fixed cost per unit.
- Operating expenses declined 30.5% in Q2 and 19.0% in the first half, mainly reflecting reduced sales and marketing spending and lower general and administrative costs. Research and development expense rose 6.7% in the first half.
- Common shares outstanding increased from 9.68 million at year-end 2022 to 29.68 million at June 30, 2023, following a February public offering of 20 million shares.
Outlook, management commentary, and risks
- Going concern: Management stated that cash and financial resources may be insufficient for anticipated needs during the twelve months following issuance of the financial statements. The filing says this raises substantial doubt about the company’s ability to continue as a going concern and that additional capital will be needed. Management expects substantial operating losses for at least the next two years; no numerical revenue or earnings guidance was provided.
- Subsequent financing: From July 11 through August 9, 2023, the company sold 116.923 million shares in three registered offerings at $0.040–$0.055 per share, generating approximately $5.2 million gross and $4.8 million net proceeds. Placement-agent warrants were also issued. These financings occurred after quarter-end and entail substantial dilution.
- Nasdaq listing: Nasdaq staff determined to delist the stock for bid-price noncompliance. The company appealed; trading was to continue pending a hearing scheduled for September 21, 2023. Stockholders approved authority for a 1-for-5 to 1-for-100 reverse split, which management expected to implement before the hearing. Neither continued listing nor a favorable appeal outcome was assured.
- Commercial and development plans: Management described a ClearUP reset: higher retail pricing, reduced underperforming marketing, new customer segments, a B2B sales portal, a distribution agreement with Cardinal Health, and planned product improvements addressing field failures. Research includes a 60-person sham-controlled postoperative-pain study and a pilot collaboration on non-invasive vagus nerve stimulation.
- Operating risks and changes: The company reduced headcount by three to 11 employees, changed CFOs, relies heavily on external providers, and outsources all contract manufacturing. Risks include financing availability, low sales volume, component supply and inflation, customer adoption, product performance, and macroeconomic uncertainty. A fulfillment agreement also imposes a $25,000 monthly minimum purchase requirement beginning April 2023.
- Management reported disclosure controls were effective and no material change in internal control over financial reporting during the quarter. No material litigation or off-balance-sheet arrangements were reported.
Key facts for investors to verify
- Whether the post-quarter offerings provide adequate runway relative to ongoing operating cash use, and the company’s cash position after August 9, 2023.
- The outcome of the Nasdaq appeal, whether a reverse split was effected, and the resulting listing status and share count.
- Whether ClearUP pricing, channel expansion, product improvements, and reduced marketing can restore sales volume while sustaining higher gross margins.
- Progress, costs, and potential commercial timelines for the clinical and vagus-nerve programs; the filing provides no assured development or revenue milestones.
- The extent of potential dilution from the offerings, placement-agent warrants, outstanding warrants, and stock options.